Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
- Drug Discovery
- ribonucleic acid
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 274931
Products – any products developed and/or manufactured based upon and/or in connection with the Patent Rights.
Licensee has developed confidential and proprietary technology relating to microRNA sequences including an algorithm for the prediction of microRNAs, techniques for validation of predicted microRNAs on a given material, microRNA expression profiling technology, analysis algorithms for the detection of biomarkers based on microRNA expression profiling and techniques for establishing the relationships between microRNAs and diseases and has identified a large number of microRNA sequences using certain of its proprietary technology and/or proprietary materials.
IPSCIO Record ID: 362451
Commercial License Licensor will grant to Licensee a worldwide, royalty-bearing, exclusive license, with the right to grant sublicenses as set forth, under the Licensor Platform Technology to Research, Develop, make, have made, use, gain Approval, Commercialize, sell, offer for sale, have sold, export and import Option Compounds and Option Products. The licenses granted to Licensee are fully sublicensable to any Affiliate of Licensee, and only sublicensable to a Third Party in connection with a sublicense of an Option Compound or Option Product for the continued Research, Development and Commercialization of such Option Compound or Option Product in accordance with the terms of this Agreement.
microRNA Antagonist means a single-stranded oligonucleotide (or a single stranded analog thereof) that is designed to interfere with or inhibit a particular microRNA.
microRNA Mimic means a double-stranded or single-stranded oligonucleotide or analog thereof with a substantially similar base composition as a particular microRNA and which is designed to mimic the activity of such microRNA.
Option Compound means either (i) with respect to Option Targets for which Licensee has selected a microRNA Antagonist under Section 3.1 above, any microRNA Antagonist discovered by Licensee or its Affiliates that modulates the expression of such Option Target where its primary mechanism of action is through its hybridization to such Option Target, or (ii) with respect to Option Targets for which Licensee has selected a microRNA Mimic under Section 3.1 above, a microRNA Mimic discovered by Licensee or its Affiliates with a substantially similar base composition as the applicable Option Target and which is designed to mimic the activity of such Option Target.
Licensor Platform Technology Patents means, (A) all Patents Controlled by Licensor on the Effective Date and listed in Agreement and (B) all Patents Controlled by Licensor during the IP Period that claim (a) microRNA Compounds in general, (b) chemistry or delivery technology useful technology useful in connection with microRNA Compounds, (c) general mechanisms of action by which a microRNA Compound modulates microRNAs, or (d) general methods of treating or preventing an Indication by modulating one or more microRNAs; provided, however, that in each case, Licensor Platform Technology Patents do not include (1) any Patents Controlled by Licensor or its Affiliates to the extent that such Patents claim (a) the sequence or a portion thereof corresponding to a specific microRNA sequence or a portion thereof, (b) the specific composition of matter of any microRNA Compound, (c) methods of using as a therapeutic any microRNA Compound; (2) the Tuschl 3 Patents; and (3) the Rockefeller Patents.
Field of use is for therapeutic applications relating to orphan diseases and oncology targets.
IPSCIO Record ID: 263910
MicroRNAs have been shown to hold tremendous potential as a new class of prospective drug targets with significant therapeutic opportunity.
MicroRNAs (miRNAs) are a recently discovered, naturally occurring form of RNAi. These small RNAs act as protein regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human diseases. In addition, microRNA expression levels have been shown to be correlated with various disease states and to hold great potential as diagnostics and prognostic markers
Licensee's lead therapeutic development program for liver cancer (hepatocellular carcinoma or HCC) has so far identified four microRNAs that when inhibited in vitro lead to a decrease in liver cancer cell proliferation.